Skip to content

An Intervention Study of GuBen PingChan Formula in the Treatment of Parkinson's Disease with Gait Disorders

A Study on the Characteristics of Gait Disorders in Parkinson's Disease and the Interventional Effects of the GuBen PingChan Formula

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084717
Enrollment
Unknown
Registered
2024-05-23
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Experimental group:Western medicine treatment combined with GuBen PingChan Formula
Control group:Western medical treatment combined with Placebo

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for MDS idiopathic Parkinson's disease, and accompanied with gait abnormalities; (2) The Hoehn & Yahr stage range is from 1~4; (3) The age range is from 40 to 80 years old, with no gender restrictions; (4) Understands and agrees to participate in this study and has signed an informed consent form; (5) Western medicine treatment: Anti-PD medications and dosages have been relatively stable for at least 3 months prior to this clinical trial, and there are no plans to change the current treatment regimen within the next 3 months.

Exclusion criteria

Exclusion criteria: (1) Suffering from other diseases that cause gait abnormalities; (2) Having parkinsonisms caused by cerebrovascular diseases, encephalitis, poisoning, medications, etc., and patients with Parkinsonism-plus syndromes; (3) Having severe heart, liver, kidney, and other diseases; (4) Having a history of dementia or mental illness; (5) Pregnant and lactating women; (6) Having participated in other clinical studies within the past 3 months.

Design outcomes

Primary

MeasureTime frame
MDS-UPDRS Part ? scores;

Secondary

MeasureTime frame
Functional Gait Assessment scores;Time of Timed Up and Go test;Freezing of Gait Questionnaire;MDS-UPDRS Part ?, ?, and ?;MDS Non-Motor Rating Scale;Montreal Cognitive Assessment;Frontal Assessment Battery;Patient Health Questionnaire-9;Generalized Anxiety Disorder-7;Blood pressure and heart rate changes in supine and standing positions;Parkinson’s disease sleep scale version 2;The 39-item Parkinson’s Disease Questionnaire;The Schwab and England Activities of Daily Living;Parkinson's Disease Traditional Chinese Medicine Syndrome Scale;

Countries

China

Contacts

Public ContactYunyun Zhang

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

zhangyyshyy@shutcm.edu.cn+86 189 3056 9983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026